Case Report: Successful conversion surgery following chemo-antiangiogenic therapy in a lung adenocarcinoma patient with active rheumatoid arthritis and rare EGFR mutation after immunotherapy-triggered flare - Takeaways - MDSpire

Case Report: Successful conversion surgery following chemo-antiangiogenic therapy in a lung adenocarcinoma patient with active rheumatoid arthritis and rare EGFR mutation after immunotherapy-triggered flare

  • By

  • Junfeng Ma

  • Peng Yan

  • Chonghua Liu

  • Yuanyuan Wang

  • June 8, 2026

  • 0 min

Share

  • 1

    A 41-year-old male with lung adenocarcinoma and active rheumatoid arthritis experienced severe RA flare after immunotherapy.

  • 2

    The patient switched to chemotherapy with bevacizumab after discontinuing immunotherapy, achieving a partial response.

  • 3

    Post-treatment imaging showed complete metabolic response of pleural nodules, allowing for successful surgical intervention.

  • 4

    Pathological assessment post-surgery confirmed downstaging to ypT2N1 with significant tumor regression.

  • 5

    The patient remained disease-free with a progression-free survival of 20 months after postoperative maintenance therapy.

Original Source(s)

Case Report: Successful conversion surgery following chemo-antiangiogenic therapy in a lung adenocarcinoma patient with active rheumatoid arthritis and rare EGFR mutation after immunotherapy-triggered flare

  • by Junfeng Ma, Peng Yan, Chonghua Liu, Yuanyuan Wang

  • June 8, 2026

Related Content

Lymphocyte CD4/CD8 ratio predicts early immune-related toxicity in lung cancer patients treated with immune checkpoint inhibitors: a single-center retrospective study

Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016–2025)

The gastrin-releasing peptide receptor in oncology: a comprehensive review of recent advances in targeted radionuclide theranostics